v3.26.3
REVENUE RECOGNITION
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
a.     Net revenues
The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows:
Three months ended September 30,Nine months ended September 30,Year ended  December 31,
20262025202620252025
United States$111,901 $96,609 $310,812 $284,024 $385,632 
International markets:
Germany24,948 20,286 72,793 58,078 79,407 
France 18,722 19,620 62,947 55,895 76,189 
Japan14,519 9,385 36,542 27,578 37,786 
Other international markets18,821 15,706 52,707 40,622 56,898 
International markets - Total77,010 64,997 224,989 182,173 250,280 
Greater China (1)
4,488 5,598 15,237 14,806 19,441 
Total net revenues$193,399 $167,204 $551,038 $481,003 $655,353 
(1) For additional information, see Notes 12 and 13 to the Consolidated Financial Statements in the 2025 10-K.

The Company's net revenues by performance period are as follows:
Three months ended September 30,Nine months ended September 30,Year ended December 31,
20262025202620252025
Net revenues recognized in the reporting period from performance obligations satisfied in:
Reporting period$179,388 $157,509 $531,432 $461,641 $632,358 
Previous periods14,011 9,695 19,606 19,362 22,995 
Total net revenues$193,399 $167,204 $551,038 $481,003 $655,353 
b.     Contract balances
The following table provides information about trade receivables, unbilled receivables and contract liabilities from contracts with customers:
September 30,
2026		December 31,
2025
UnauditedAudited
Trade receivables$100,496 $81,648 
Unbilled receivables$7,764 $7,787 
Deferred revenues (short-term contract liabilities)$(17,519)$(15,948)
During the nine months ended September 30, 2026 and 2025 and the year ended December 31, 2025 the Company recognized $15,948, $14,225 and $14,225, respectively, which were included in the deferred revenues (short-term contract liability) balance at January 1, 2026 and 2025.